MHRA

GLP-1 drugs: clinical trends, safety, and market shifts

291 clusters · 1104 sources · last updated about 24 hours ago

Latest: Novo Nordisk faces lawsuits over Ozempic and NAION risks

Since mid-2026, the expansion of GLP-1 agents for obesity has been accompanied by intensified safety monitoring and evolving clinical data. Research suggests secondary benefits, including a 21% lower risk of fragility fr

uniQure Huntington’s disease gene therapy regulatory filings

3 clusters · 9 sources · last updated 8 days ago

Latest: uniQure releases mixed 48-month clinical data for AMT-130

uniQure has initiated regulatory approval processes for AMT-130, a gene therapy designed to treat the underlying cause of Huntington’s disease. The company submitted a Biologics License Application to the U.S. Food and D

Global safety concerns regarding GLP-1 weight loss drugs

2 clusters · 11 sources · last updated 18 days ago

Latest: Weight loss drugs linked to serious side effects and vision loss

Health authorities are monitoring a surge in reported adverse reactions and deaths linked to GLP-1 receptor agonists used for weight loss and diabetes, including semaglutide, tirzepatide, and liraglutide. Initial report

Safety warnings for over-the-counter painkillers

2 clusters · 6 sources · last updated about 1 month ago

Latest: Painkiller safety: Risks of misuse and dosage guidelines

Medical professionals and regulatory agencies are issuing warnings regarding the risks associated with the misuse of common over-the-counter painkillers, including ibuprofen, paracetamol, diclofenac, and naproxen. Initi